Deferred Federal Income Tax Expense (Benefit) of Keenova Therapeutics plc from 30 Sep 2011 to 27 Dec 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.
Summary
Keenova Therapeutics plc annual and quarterly Deferred Federal Income Tax Expense (Benefit) in USD history and change rate from 30 Sep 2011 to 27 Dec 2024.
  • Keenova Therapeutics plc Deferred Federal Income Tax Expense (Benefit) for the quarter ending 29 Dec 2023 was $6,100,000.
  • Keenova Therapeutics plc annual Deferred Federal Income Tax Expense (Benefit) for 2024 was $85,700,000.
  • Keenova Therapeutics plc annual Deferred Federal Income Tax Expense (Benefit) for 2021 was $59,500,000, a 158% decline from 2020.
  • Keenova Therapeutics plc annual Deferred Federal Income Tax Expense (Benefit) for 2020 was $102,200,000.
Source SEC data
View on sec.gov
Deferred Federal Income Tax Expense (Benefit), Annual (USD)
Deferred Federal Income Tax Expense (Benefit), YoY Annual Change (%)
Deferred Federal Income Tax Expense (Benefit), Quarterly (USD)

Keenova Therapeutics plc Annual Deferred Federal Income Tax Expense (Benefit) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $85,700,000 30 Dec 2023 27 Dec 2024 10-K 13 Mar 2025 2024 FY
2021 $59,500,000 -$161,700,000 -158% 26 Dec 2020 31 Dec 2021 10-K 26 Mar 2024 2023 FY
2020 $102,200,000 +$103,300,000 28 Dec 2019 25 Dec 2020 10-K 03 Mar 2023 2022 FY
2019 $1,100,000 -$2,500,000 -179% 29 Dec 2018 27 Dec 2019 10-K 15 Mar 2022 2021 FY
2018 $1,400,000 +$800,000 +133% 30 Dec 2017 28 Dec 2018 10-K 10 Mar 2021 2020 FY
2017 $600,000 -$100,000 -14% 31 Dec 2016 29 Dec 2017 10-K 26 Feb 2020 2019 FY
2016 $700,000 +$1,500,000 26 Sep 2015 30 Sep 2016 10-K 26 Feb 2019 2018 FY
2015 $800,000 +$41,100,000 +98% 27 Sep 2014 25 Sep 2015 10-K 27 Feb 2018 2017 FY
2014 $41,900,000 -$23,600,000 -129% 28 Sep 2013 26 Sep 2014 10-K 29 Nov 2016 2016 FY
2013 $18,300,000 -$23,600,000 -445% 29 Sep 2012 27 Sep 2013 10-K 24 Nov 2015 2015 FY
2012 $5,300,000 -$32,500,000 -86% 01 Oct 2011 28 Sep 2012 8-K 03 Apr 2015 2014 FY
2011 $37,800,000 25 Sep 2010 30 Sep 2011 10-K 13 Dec 2013 2013 FY

Keenova Therapeutics plc Quarterly Deferred Federal Income Tax Expense (Benefit) (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2023 $6,100,000 29 Dec 2023 10-K 13 Mar 2025 2024 FY
Q4 2016 $500,000 30 Dec 2016 10-K 26 Feb 2019 2018 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.